These patents join 11 US patents and 28 foreign patents already obtained by Echo Therapeutics.

Echo Therapeutics’ Symphony tCGM System is a non-invasive, wireless, tCGM system and the Prelude SkinPrep System for transdermal drug delivery.

Echo Therapeutics chairman and CEO Patrick Mooney said they have recognized the value that their non-invasive, glucose monitoring technology can provide, and these patents reinforce this belief, further demonstrating the proprietary nature of their technology.